The RDCRN-VCRC Patient Contact Registry is an online method by which patients with vasculitis can register themselves with the Vasculitis Clinical Research Consortium (VCRC) in order to be contacted in the future about clinical research opportunities and updates on the progress of the VCRC research projects. Participants in the Registry receive monthly informational newsletters. The registry was launched in 2005 to address a major objective of the Rare Disease Clinical Research Network (RDCRN) to directly engage patients and their advocates in clinical research and to establish infrastructure to make meaningful large-scale studies possible in rare diseases. The Patient Contact Registry is the largest and fastest growing research infrastructure within the VCRC and is the largest such registry within the RDCRN. At present >3,700 subjects with vasculitis (and growing) have enrolled in the Registry, representing all 50 states in the US and an expanding international presence. Three research studies have been successfully completed through the Registry leading to publications of study results in high-profile journals! The aims of this project are to maintain and expand recruitment of patients with vasculitis in the VCRC Patient Contact Registry;to perform online-based research on subjects with different forms of vasculitis, including projects related to social science, comparative effectiveness research and patient-reported outcomes;and to promote patient education and awareness about clinical research in vasculitis. Through partnership with patient advocacy groups in vasculitis, recruitment of new participants remains strong. A series of new proposed projects underscore the importance of the registry to conduct meaningful and innovative research in vasculitis, including an exciting new project to establish a Vasculitis Pregnancy Registry (V-PREG) to learn about the experiences of women with vasculitis who become pregnant. The VCRC Patient Contact Registry provides exciting opportunities to engage patients with vasculitis from all over the world in research studies and educational programs. The VCRC is at the forefront of using the internet to directly work with patients with these rare diseases.
The VCRC Patient Contact Registry is a novel and efficient way to reach patients with rare diseases. Connecting with patients online is an important way to engage patients with vasculitis who may have no other access to participate in research. Through online clinical research studies, patient education, and promotion of awareness about vasculitis, the VCRC Patient Contact Registry fulfills the mission of the RDCRN.
|Merkel, Peter A; Xie, Gang; Monach, Paul A et al. (2017) Identification of Functional and Expression Polymorphisms Associated With Risk for Antineutrophil Cytoplasmic Autoantibody-Associated Vasculitis. Arthritis Rheumatol 69:1054-1066|
|Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Takayasu Arteritis. Arthritis Rheumatol 69:846-853|
|Milman, N; Boonen, A; Tugwell, P et al. (2017) Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise. Scand J Rheumatol 46:112-117|
|Langford, Carol A; Cuthbertson, David; Ytterberg, Steven R et al. (2017) A Randomized, Double-Blind Trial of Abatacept (CTLA-4Ig) for the Treatment of Giant Cell Arteritis. Arthritis Rheumatol 69:837-845|
|Carmona, F David; Coit, Patrick; Saruhan-Direskeneli, Güher et al. (2017) Analysis of the common genetic component of large-vessel vasculitides through a meta-Immunochip strategy. Sci Rep 7:43953|
|Selewski, David T; Thompson, Aliza; Kovacs, Sarrit et al. (2017) Patient-Reported Outcomes in Glomerular Disease. Clin J Am Soc Nephrol 12:140-148|
|Oommen, Esha; Hummel, Amber; Allmannsberger, Lisa et al. (2017) IgA antibodies to myeloperoxidase in patients with eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Clin Exp Rheumatol 35 Suppl 103:98-101|
|Gopaluni, Seerapani; Smith, Rona M; Lewin, Michelle et al. (2017) Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial. Trials 18:112|
|Carmona, F David; Vaglio, Augusto; Mackie, Sarah L et al. (2017) A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. Am J Hum Genet 100:64-74|
|Sreih, Antoine G; Alibaz-Oner, Fatma; Kermani, Tanaz A et al. (2017) Development of a Core Set of Outcome Measures for Large-vessel Vasculitis: Report from OMERACT 2016. J Rheumatol 44:1933-1937|
Showing the most recent 10 out of 72 publications